At a cost-effectiveness threshold of $95,000 per quality-adjusted life-year (QALY), the prefusion F protein-based vaccines Arexvy and Abrysvo would provide direct health benefits by reducing
In adults aged 60 years or older, a single dose of an mRNA-based respiratory syncytial virus (RSV) vaccine encoding the stabilized RSV prefusion F glycoprotein
In a cluster-randomized observational study, adults aged 50 to 64 years had a lower incidence of influenza when vaccinated with high-dose recombinant versus egg-based, standard-dose
While awaiting the availability of next-generation influenza vaccines, clinicians have the task of convincing patients of the value of influenza immunization in a season with
In Sweden, people vaccinated against COVID-19 before a SARS-CoV-2 infection had a lower risk of developing post-COVID-19 condition (PCC; “long COVID”), according to a register-based
Coadministration of the BNT162b2 BA.4/5 bivalent mRNA COVID-19 vaccine (BNT162b2-biv) and seasonal influenza vaccine (SIV) in the community setting produced similar effectiveness and outcomes as when
While the effectiveness of live zoster vaccine against herpes zoster waned substantially following administration, some protection remained after 10 years in a real-world study, particularly
Two studies examine parental trust in vaccine information and polarization of attitudes during the COVID-19 pandemic and identify a number of vaccine concerns that can
In a cohort study, unvaccinated people with COVID-19 had a 62% higher chance of developing new-onset diabetes mellitus (DM), while vaccinated individuals with breakthrough COVID-19
The prevalence of human papillomavirus (HPV) vaccine-types and closely related HPV types declined sharply among vaccine-eligible females during 10 years of high-coverage HPV vaccination in